Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies

Share

Supporters

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC